Business Wire

MindMaze Drives Future of Upper-Limb Neural Recovery with a First-in-Class Smart Peripheral for Hand Dexterity Assessment and Training

14.2.2023 18:00:00 EET | Business Wire | Press release

Share

MindMaze, a global pioneer in the development of AI-driven digital neurotherapeutics, is proud to announce the US and EU launch of Izar ®1, a first-of-its-kind, FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function. Izar is designed to fill a critical gap in neurological care today and aims to be the most effective hand dexterity and strength treatment in a wide range of neurological conditions. This proprietary peripheral is a significant step forward in MindMaze’s efforts to deliver more effective patient care through combinations of smart peripherals with its growing portfolio of Digital Care and Digital Medicine solutions. Izar is part of a comprehensive omnisite approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Izar device: hand therapy solution (Photo: Business Wire)

Our hands are vital for everyday life – from buttoning up a shirt, to eating, typing, or driving a car – hands are essential for personal and economic independence. Impaired hand function is one of the most common disabilities after stroke with paralysis of the hand and upper limb occurring in up to 87% of all stroke survivors. Not surprisingly, patients rate hand recovery as one of the most important factors associated with their improved quality of life and independence. Yet today hands remain incredibly challenging to treat under the current standard of care given the inherent limitations in time, resources and technology. Izar allows clinics to finally address the unmet or underserved need of hand recovery through new in-clinic or remotely supervised self-training programs at home, increasing the dose and quality of training.

Izar is a hyper-sensitive controller built from the ground-up to train and assess both dexterity and strength, through capture of the fine grasp forces and wrist movements required to carry out activities of daily living. Izar can detect sub-newton level patient finger and hand forces, enabling treatment in the most impaired patient populations. This simple and highly portable controller is accompanied by proprietary and engaging gaming content that allows patients to self-train, either in-clinic, at bedside, or in the comfort of their home, dramatically enhancing and expanding training opportunities.

“It is very exciting to have a device for the hand that has the versatility of Izar. It can serve as a controller during reach-to-grasp movements, as a trainer of grip force gradation, and as an assessor of dexterity,” said Professor John Krakauer, M.D., Ph.D. and MindMaze’s Chief Medical Director. “The device is also highly portable, so it can be used across the continuum of care, which is important as the upper limb, and the hand in particular, gets relatively neglected in neurorehabilitation.”

Leading global centers such as Shirley Ryan Ability Lab in the US, University College London in the United Kingdom, and The University of Aukland in New Zealand are already actively using Izar in pioneering clinical research. Izar was subjected to rigorous pre-launch testing across nine sites and delivered over 250 hours of active supervised and self-training therapy time in 250 patients, receiving unanimously positive feedback.

“With Izar I felt my hand again for the first time, I could even actively move it a bit and I saw that on the screen. It gave me a lot of hope,” said a Berit H., a patient from the P.A.N. Zentrum Centre in Germany. Julia Knape, a therapist from the same program added: “Our clients were actually surprised to see that they still had hand-finger functions. Through the visual feedback of even the smallest functions, they were more motivated for the therapy.”

Izar is available today in the US as well as European countries including France, Switzerland and Germany with content that enables training of dexterous grasp, pinch and grip. Future software content will unlock training content for wrist, bilateral movements, combination movements of the upper-limb and hand, as well as dexterity assessments for hand and wrist.

1Izar is a trademark of MindMaze Group SA, registered in the European Union and in Switzerland.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

pr@mindmaze.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Infobip Named a Leader in the 2026 Gartner® Magic Quadrant™ for Communications Platform as a Service18.5.2026 17:25:00 EEST | Press release

Infobip is excited to share that global AI-first cloud communications platform Infobip has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Communications Platform as a Service. Check back for a complimentary copy of the full report soon! In Infobip’s view, this recognition reflects what the company has spent 20 years building: a communications platform that stays focused on what customers actually need and evolves as markets change. Infobip believes that recognition in a fast-moving market comes not from chasing trends, but from disciplined execution and a clear long-term vision. As Infobip marks its 20th year of operations, the company thinks the shift to agentic AI represents the most significant transformation in customer communications in our history. Infobip believes enterprises need a partner that empowers them to move from campaigns and rigid workflows to autonomous, goal-driven interactions, while retaining the openness and flexibility to adapt as the technol

Seoul Design Foundation Announces ‘Seoul Design AI Film Festival’ Call for Entries18.5.2026 17:00:00 EEST | Press release

The Seoul Design Foundation (CEO Cha Kang Heui) is inviting visionaries worldwide to the Seoul Design AI Film Festival (SDAFF). This global competition aims to redefine the Dongdaemun Design Plaza (DDP)—the world’s largest atypical architecture—as a premier destination for AI-driven media art. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518044745/en/ An official poster for Seoul Design AI Film Festival (Image: Seoul Design Foundation) The DDP’s 222-meter curved exterior wall, a Guinness World Record holder for the "World's Largest 3D Mapping on an Atypical Building," will serve as the digital canvas for the winners. ‘Seoul Light DDP’ has already achieved global acclaim by winning the world’s top three design awards: iF, Red Dot, and IDEA. Bridging AI Technology and K-Culture The festival seeks high-quality video works that blend artistic inspiration with cutting-edge AI technology. The competition features two main cat

SERI Lugano Launches International Scientific Outreach Initiative on Light-Based Neuroscience and Pineal Gland Research18.5.2026 16:38:00 EEST | Press release

As scientific interest in light-based stimulation, neuroendocrine regulation, and integrative medicine continues to grow internationally, the Switzerland Eye Research Institute (SERI Lugano) has launched a new international scientific outreach initiative focused on public engagement and interdisciplinary research communication in neuroscience and cellular modulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515840289/en/ Ophthalmologist Roberto Pinelli explains, in an engaging personal narrative style, his unique methods for using a combination of light, sound, and nutraceuticals to non-invasively activate the pineal gland to promote cellular reju­venation, decrease aging, and improve overall well-being. Supported by case studies and peer-reviewed research, Pinelli’s method centers on using photons to convey vibrational energy through the eyes to target areas of the body with the sinergic use of sound vibrations and

TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM18.5.2026 16:00:00 EEST | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces it has agreed to acquire Terhills Resort in Belgium from LRM. The transaction is expected to close on 29 May 2026. Operated by Center Parcs, the premium holiday park spans 63 hectares and comprises 250 waterfront cottages alongside central leisure facilities, set within a unique natural environment at the gateway to Hoge Kempen National Park. Center Parcs will remain the operator of the resort for at least the next 10 years, ensuring continuity for guests and supporting the long-term positioning of the resort as a leading leisure destination in Limburg, one of Flanders’ most distinctive tourism regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513424487/en/ Opened in 2021, Terhills Resort forms part of the broader long-term transformation of the surrounding area into a leading nature, tourism and leisure destination.

Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 15:30:00 EEST | Press release

Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker services across the full drug development lifecycle, from preclinical studies through post-approval. Its advanced technology suite includes cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, supporting both small molecules and complex therapeutic modalities such as peptides, antibodies, oligonucleotides, and cell and gene therapies. “Our new Gothenburg laboratory is purpose-built to address t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye